{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:33:27Z","timestamp":1792802007352,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"PreludeDx","id":[{"id":"https:\/\/ror.org\/055298e12","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Breast-conserving surgery (BCS) followed by adjuvant radiotherapy (RT) is a standard treatment for ductal carcinoma in situ (DCIS). A low-risk patient subset that does not benefit from RT has not yet been clearly identified. The DCISionRT test provides a clinically validated decision score (DS), which is prognostic of 10-year in-breast recurrence rates (invasive and non-invasive) and is also predictive of RT benefit. This analysis presents final outcomes from the PREDICT prospective registry trial aiming to determine how often the DCISionRT test changes radiation treatment recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Overall, 2496 patients were enrolled from February 2018 to January 2022 at 63 academic and community practice sites and received DCISionRT as part of their care plan. Treating physicians reported their treatment recommendations pre- and post-test as well as the patient\u2019s preference. The primary endpoint was to identify the percentage of patients where testing led to a change in RT recommendation. The impact of the test on RT treatment recommendation was physician specialty, treatment settings, individual clinical\/pathological features and RTOG 9804 like criteria. Multivariate logisitc regression analysis was used to estimate the odds ratio (ORs) for factors associated with the post-test RT recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      RT recommendation changed 38% of women, resulting in a 20% decrease in the overall recommendation of RT (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). Of those women initially recommended no RT (\n                      <jats:italic>n<\/jats:italic>\n                      = 583), 31% were recommended RT post-test. The recommendation for RT post-test increased with increasing DS, from 29% to 66% to 91% for DS &lt;2, DS 2\u20134, and DS &gt;4, respectively. On multivariable analysis, DS had the strongest influence on final RT recommendation (odds ratio 22.2, 95% confidence interval 16.3\u201330.7), which was eightfold greater than clinicopathologic features. Furthermore, there was an overall change in the recommendation to receive RT in 42% of those patients meeting RTOG 9804-like low-risk criteria.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The test results provided information that changes treatment recommendations both for and against RT use in large population of women with DCIS treated in a variety of clinical settings. Overall, clinicians changed their recommendations to include or omit RT for 38% of women based on the test results. Based on published clinical validations and the results from current study, DCISionRT may aid in preventing the over- and undertreatment of clinicopathological \u2018low-risk\u2019 and \u2018high-risk\u2019 DCIS patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov identifier: NCT03448926 (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03448926\">https:\/\/clinicaltrials.gov\/study\/NCT03448926<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-024-15566-5","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T10:02:14Z","timestamp":1719309734000},"page":"5919-5928","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The Clinical Utility of a 7-Gene Biosignature on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery: An Updated Analysis of the DCISionRT\u00ae PREDICT Study"],"prefix":"10.1245","volume":"31","author":[{"given":"Chirag","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pat","family":"Whitworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank A.","family":"Vicini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Narod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naamit","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin R.","family":"Jhawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tari A.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Mittendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawna C.","family":"Willey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Rabinovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linsey","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushka","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parul N.","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauri","family":"Bedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Templeton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheree","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Gabordi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lonika","family":"Majithia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina L.","family":"Mirabeau-Beale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent J.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arica","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Pellicane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Maganini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadia","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhara M.","family":"MacDermed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Small","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karuna","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Borgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C.","family":"Shivers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"Bremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"issue":"1","key":"15566_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin."},{"issue":"1","key":"15566_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21442.","journal-title":"CA Cancer J Clin."},{"issue":"14","key":"15566_CR3","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMra031301","volume":"350","author":"HJ Burstein","year":"2004","unstructured":"Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med. 2004;350(14):1430\u201341. https:\/\/doi.org\/10.1056\/NEJMra031301.","journal-title":"N Engl J Med."},{"issue":"5","key":"15566_CR4","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1097\/SLA.0000000000002239","volume":"267","author":"LE Elshof","year":"2018","unstructured":"Elshof LE, Schmidt MK, Rutgers EJT, van Leeuwen FE, Wesseling J, Schaapveld M. Cause-specific mortality in a population-based cohort of 9799 women treated for ductal carcinoma in situ. Ann Surg. 2018;267(5):952\u20138. https:\/\/doi.org\/10.1097\/SLA.0000000000002239.","journal-title":"Ann Surg."},{"issue":"9","key":"15566_CR5","doi-asserted-by":"publisher","first-page":"e2017124","DOI":"10.1001\/jamanetworkopen.2020.17124","volume":"3","author":"V Giannakeas","year":"2020","unstructured":"Giannakeas V, Sopik V, Narod SA. Association of a diagnosis of ductal carcinoma in situ with death from breast cancer. JAMA Netw Open. 2020;3(9):e2017124. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.17124.","journal-title":"JAMA Netw Open."},{"issue":"7","key":"15566_CR6","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jamaoncol.2015.2510","volume":"1","author":"SA Narod","year":"2015","unstructured":"Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol. 2015;1(7):888\u201396. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2510.","journal-title":"JAMA Oncol."},{"key":"15566_CR7","doi-asserted-by":"publisher","unstructured":"Early Breast Cancer Trialists' Collaborative Group, Correa C, McGale P, et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010;2010(41):162-77. https:\/\/doi.org\/10.1093\/jncimonographs\/lgq039","DOI":"10.1093\/jncimonographs\/lgq039"},{"issue":"2","key":"15566_CR8","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s10549-013-2539-5","volume":"139","author":"LC Collins","year":"2013","unstructured":"Collins LC, Achacoso N, Haque R, et al. Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ. Breast Cancer Res Treat. 2013;139(2):453\u201360. https:\/\/doi.org\/10.1007\/s10549-013-2539-5.","journal-title":"Breast Cancer Res Treat."},{"issue":"12","key":"15566_CR9","doi-asserted-by":"publisher","first-page":"djv263","DOI":"10.1093\/jnci\/djv263","volume":"107","author":"M Worni","year":"2015","unstructured":"Worni M, Akushevich I, Greenup R, et al. Trends in treatment patterns and outcomes for ductal carcinoma in situ. J Natl Cancer Inst. 2015;107(12):djv263. https:\/\/doi.org\/10.1093\/jnci\/djv263.","journal-title":"J Natl Cancer Inst."},{"issue":"6","key":"15566_CR10","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/jnci\/djr027","volume":"103","author":"IL Wapnir","year":"2011","unstructured":"Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103(6):478\u201388. https:\/\/doi.org\/10.1093\/jnci\/djr027.","journal-title":"J Natl Cancer Inst."},{"key":"15566_CR11","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Breast Cancer. 2023; Version 4.2023, 23 March 2023. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. 2023; Version 4.2023, March 23, 2023."},{"issue":"11","key":"15566_CR12","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1093\/jnci\/djad117","volume":"115","author":"JK Kresovich","year":"2023","unstructured":"Kresovich JK, O\u2019Brien KM, Xu Z, Weinberg CR, Sandler DP, Taylor JA. Changes in methylation-based aging in women who do and do not develop breast cancer. J Natl Cancer Inst. 2023;115(11):1329\u201336. https:\/\/doi.org\/10.1093\/jnci\/djad117.","journal-title":"J Natl Cancer Inst."},{"issue":"6","key":"15566_CR13","doi-asserted-by":"publisher","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","volume":"20","author":"WJ Gradishar","year":"2022","unstructured":"Gradishar WJ, Moran MS, Abraham J, et al. Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(6):691\u2013722. https:\/\/doi.org\/10.6004\/jnccn.2022.0030.","journal-title":"J Natl Compr Canc Netw."},{"issue":"1","key":"15566_CR14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10549-023-07036-5","volume":"202","author":"KA Hashiba","year":"2023","unstructured":"Hashiba KA, Bahl M. Ipsilateral tumor recurrence risk in women with ductal carcinoma in situ: application of the Van Nuys Prognostic Index and the Memorial Sloan Kettering Cancer Center nomogram. Breast Cancer Res Treat. 2023;202(1):185\u201390. https:\/\/doi.org\/10.1007\/s10549-023-07036-5.","journal-title":"Breast Cancer Res Treat."},{"issue":"3","key":"15566_CR15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/jnci\/djp485","volume":"102","author":"CJ Allegra","year":"2010","unstructured":"Allegra CJ, Aberle DR, Ganschow P, et al. National institutes of health state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ September 22\u201324, 2009. J Natl Cancer Inst. 2010;102(3):161\u20139. https:\/\/doi.org\/10.1093\/jnci\/djp485.","journal-title":"J Natl Cancer Inst."},{"key":"15566_CR16","unstructured":"Public Law 114\u2013255\u2014Dec. 13, 2016. Available at: https:\/\/www.govinfo.gov\/content\/pkg\/PLAW-114publ255\/pdf\/PLAW-114publ255.pdf."},{"issue":"23","key":"15566_CR17","doi-asserted-by":"publisher","first-page":"5895","DOI":"10.1158\/1078-0432.CCR-18-0842","volume":"24","author":"T Bremer","year":"2018","unstructured":"Bremer T, Whitworth PW, Patel R, et al. A biological signature for breast ductal carcinoma in situ to predict radiotherapy benefit and assess recurrence risk. Clin Cancer Res. 2018;24(23):5895\u2013901. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0842.","journal-title":"Clin Cancer Res."},{"key":"15566_CR18","doi-asserted-by":"publisher","first-page":"1069059","DOI":"10.3389\/fonc.2023.1069059","volume":"13","author":"D Dabbs","year":"2023","unstructured":"Dabbs D, Mittal K, Heineman S, et al. Analytical validation of the 7-gene biosignature for prediction of recurrence risk and radiation therapy benefit for breast ductal carcinoma in situ. Front Oncol. 2023;13:1069059. https:\/\/doi.org\/10.3389\/fonc.2023.1069059.","journal-title":"Front Oncol."},{"issue":"1","key":"15566_CR19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ijrobp.2022.06.072","volume":"115","author":"FA Vicini","year":"2023","unstructured":"Vicini FA, Mann GB, Shah C, et al. A novel biosignature identifies patients with DCIS with high risk of local recurrence after breast conserving surgery and radiation therapy. Int J Radiat Oncol Biol Phys. 2023;115(1):93\u2013102. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.06.072.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"Suppl 3","key":"15566_CR20","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1245\/s10434-021-10138-3","volume":"28","author":"C Shah","year":"2021","unstructured":"Shah C, Bremer T, Cox C, et al. Correction to: the clinical utility of DCISionRT\u00ae on radiation therapy decision making in patients with ductal carcinoma in situ following breast-conserving surgery. Ann Surg Oncol. 2021;28(Suppl 3):878. https:\/\/doi.org\/10.1245\/s10434-021-10138-3.","journal-title":"Ann Surg Oncol."},{"issue":"23","key":"15566_CR21","doi-asserted-by":"publisher","first-page":"6103","DOI":"10.3390\/cancers13236103","volume":"13","author":"F W\u00e4rnberg","year":"2021","unstructured":"W\u00e4rnberg F, Karlsson P, Holmberg E, et al. Prognostic Risk assessment and prediction of radiotherapy benefit for women with ductal carcinoma in situ (DCIS) of the breast, in a randomized clinical trial (SweDCIS). Cancers. 2021;13(23):6103.","journal-title":"Cancers."},{"issue":"15","key":"15566_CR22","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.1158\/1078-0432.CCR-19-1152","volume":"26","author":"S Weinmann","year":"2020","unstructured":"Weinmann S, Leo MC, Francisco M, et al. Validation of a ductal carcinoma in situ biomarker profile for risk of recurrence after breast-conserving surgery with and without radiotherapy. Clin Cancer Res. 2020;26(15):4054\u201363. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1152.","journal-title":"Clin Cancer Res."},{"issue":"32","key":"15566_CR23","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1200\/JCO.21.01083","volume":"39","author":"B McCormick","year":"2021","unstructured":"McCormick B, Winter KA, Woodward W, et al. Randomized phase III trial evaluating radiation following surgical excision for good-risk ductal carcinoma in situ: long-term report from NRG oncology\/RTOG 9804. J Clin Oncol. 2021;39(32):3574\u201382. https:\/\/doi.org\/10.1200\/JCO.21.01083.","journal-title":"J Clin Oncol."},{"issue":"33","key":"15566_CR24","doi-asserted-by":"publisher","first-page":"3938","DOI":"10.1200\/JCO.2015.60.8588","volume":"33","author":"LJ Solin","year":"2015","unstructured":"Solin LJ, Gray R, Hughes LL, et al. Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study. J Clin Oncol. 2015;33(33):3938\u201344. https:\/\/doi.org\/10.1200\/JCO.2015.60.8588.","journal-title":"J Clin Oncol."},{"key":"15566_CR25","unstructured":"R Core Team, 2016. R: A Language and Environment for Statistical Computing, Vienna, Austria. Available at: https:\/\/www.R-project.org\/."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15566-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-15566-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15566-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T14:25:26Z","timestamp":1722867926000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-15566-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["15566"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-15566-5","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]},"assertion":[{"value":"23 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Troy Bremer, Steven C. Shivers, Karuna Mittal, and Pat Whitworth are employees of, and have stock options in, PreludeDx. Troy Bremer is Chief Science Officer of PreludeDx, co-invented the technology, and is named as an inventor of DCISionRT<sup>\u00ae<\/sup>. Frank Vicini, Chirag Shah, and Steven Narod are consultants for PreludeDx. All other co-authors were local principal investigators for the PREDICT Registry and their institutions received research funding to cover the costs of IRB review, patient enrollment, and completion of case report forms. Frank Vicini is also a consultant for Impedimed. Sachin Jhawar received grant funding from Varian Medical Systems to study the role of the oropharyngeal microbiome in head and neck cancer patients. Tari King declares speakers honoraria and compensated advisory board from Exact Sciences; Faculty PrecisCa Cancer Information Services. John Vargo declares Consulting Elsevier Clinical Pathways. Parul Barry declares El-Sevier Pathways Consultant; Talks for Oncolive\/Varian on breast cancer and women in medicine; ACRO Board Member, Chair of ASTRO HEDI Education, Chair of the WIMS Scientific Committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"DISCLOSURES"}}]}}